
Craig Hofmeister
@eaglemyeloma
Clinical investigator at Emory focused on myeloma & amyloidosis, dreaming of curing cancer while improving quality.
ID: 2234845399
https://winshipcancer.emory.edu/craig-hofmeister 07-12-2013 17:42:56
2,2K Tweet
3,3K Followers
321 Following

Wonderful that beans will finally have its well deserved place in the guidelines 🌱 Christopher Gardner










Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma | Journal for ImmunoTherapy of Cancer MCW Cancer Center Saurabh Chhabra Phari jitc.bmj.com/content/13/1/e…



"It is a misnomer to call these funds indirect costs. They are essential to ...research. The environment in which research is conducted is highly specialized and costly. The government's share is not a give- away." Preach Dr. Holden Thorp, dormant account pubmed.ncbi.nlm.nih.gov/39932436/

NPCs in congress - spot on. What to do? Support campaign finance reform via Brennan Center so billionaires stay out of government. nytimes.com/2025/02/16/opi…


Lack of RCT data on ASCT in AL Amyloidosis (+ ⬆️ TRM vs myeloma) makes decisions tough when VGPR/CR post-DaraVCd. This new TRM risk model by Eli Muchtar Mayo Amyloid will help us better weigh risks/benefits in clinic! CAMP@CUIMC search.app/z6SjVNVXqTrmeX…
